At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 367 enrolled

Drug / intervention

Nivolumab +4 morebiological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02864251

NCT02864251Phase 3Completed

Compare CT.gov

Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy

Bristol-Myers Squibb·interventional·Posted Aug 11, 2016·Updated Sep 28, 2023

In Brief

A Phase 3 clinical trial evaluating Nivolumab, Ipilimumab, and 3 other interventions for Non-Small-Cell Lung Carcinoma. Completed, enrolled 367 participants across 109 sites in 10 countries.

Detailed Summary

The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNon-Small-Cell Lung Carcinoma

CountriesCanada, China, France, Hong Kong, Japan, Singapore, South Korea, Spain, Taiwan, United States

CollaboratorsOno Pharmaceutical Co., Ltd.

Timeline

Phase 3CompletedFinished

2017201820192020202120222023202420252026

First PostedAug 2016

Enrollment StartMar 2017

Primary CompletionJan 2022

Study CompletionOct 2022

TodayJul 2026

First PostedAug 11, 2016

Enrollment StartMar 17, 2017

Primary CompletionJan 20, 2022

Study CompletionOct 17, 2022

TodayJul 2, 2026

Enrollment to primary: 4.8 yearsPosted 9.9 years ago